Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Huntington Memorial Hospital Is First In Southern California To Install Toshiba's Aquilion One Dynamic Volume CT System
To meet the growing needs of its high-volume emergency department (ED), Huntington Memorial Hospital has acquired Toshiba"s Aquilion® ONE dynamic volume CT system.
generic viagra online
PharmAthene Submits Proposal To BARDA In Response To Broad Agency Announcement For Advanced Research And Development For Valortim(R)
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) in response to a Broad Agency Announcement (BAA-BARDA-09-34) for advanced research and development of medical countermeasures for chemical, biological, radiological and nuclear threats. PharmAthene has requested funding to further develop Valortim(R), a fully human monoclonal antibody, for the prevention and treatment of anthrax infection. To date, the Company has received funding commitments from the U. S. government totaling up to $24 million to advance the development of Valortim(R).
News of the day
ACMG Joins Lawsuit Challenging Patents On Breast Cancer Genes
The American College of Medical Genetics (ACMG) has joined the Association for Molecular Pathology, the College of American Pathologists, and the American Society for Clinical Pathology in a lawsuit filed today charging that patents on the human genes associated with breast and ovarian cancer interfere with diagnostic testing, stifle research and limit women"s options regarding their health care. The lawsuit challenges patents on the BRCA1 and BRCA2 genes, which are responsible for most cases of hereditary breast and ovarian cancers. Because these genes are "products of nature," the ACMG believes that granting patents on them is illegal.
Nutrition

Two Day Treatment Of Auditory Hallucinations By High Frequency RTMS Guided By Cerebral Imaging: A 6 Months Follow-up Study

Auditory hallucinations are one of the more disturbing features of schizophrenia, and tend to persist even when patients are treated with conventional medication treatments. Researchers from the University of Caen, France, report on a new treatment for hallucinations at the meeting of the Organization for Human Brain Mapping. They used a technique called Repetitive Transcranial Magnetic Stimulation- rTMS, which sends magnetic pulses at high frequency (20 Hz) over the brain surface. By placing the pulses guided by anatomical and functional cerebral imaging over the auditory cortex where hallucinations are generated, they found a significant reduction in auditory hallucinations that lasted for nearly 2 weeks following the treatment; 2 patients were hallucination free after 6 months. While the study is still preliminary, it suggests the potential for 20 Hz- rTMS as a new, noninvasive approach to treatment of schizophrenia that is relatively safe and free of side effects. Authors: S Dollfus, A Montagne-Larmurier, A Razafimandimby, R Morello, O Etard Centre Hospitalier Universitaire, Caen, France Organization for Human Brain Mapping


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009